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sions. CONCLUSIONS: When comparing well-matched patients undergoing TKA, 
significantly better clinical and economic outcomes were found using local infiltra-
tion of LB rather than continuous nerve block with elastomeric pumps to manage 
postsurgical pain.
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OBJECTIVES: Erythropoietin has been widely adapted into clinical practice in ortho-
pedic surgery to prevent anemia and ultimately lower the use of allogeneic blood 
transfusions. Its safety and efficacy has been shown in various randomized clini-
cal trials. Questions regarding the cost-effectiveness of this treatment, however, 
have yet to be answered conclusively. Notably, current indication guidelines are 
based on preoperative hemoglobin levels, but do not differentiate between total hip 
arthroplasty (THA) and total knee arthroplasty (TKA). This literature review aims 
at analyzing the cost-effectiveness of preoperative erythropoietin as blood spar-
ing measure in patients undergoing elective orthopedic surgery, specifically THA 
and TKA. Additionally, patient inclusion criteria are analyzed in order to identify 
the potentially most cost-effective patient subgroups, e.g. based on preoperative 
hemoglobin levels, primary or revisional surgery and THA versus TKA. METHODS: 
Systematic literature review. RESULTS: A MEDLINE database search and subsequent 
exclusion of irrelevant or inaccessible papers resulted in the inclusion of 8 research 
articles that at least partially performed a cost-effectiveness or cost-benefit analysis 
of erythropoietin in orthopedic surgery. Four of the studies concluded erythropoi-
etin is not cost-effective, three studies were not able to draw a conclusion based on 
their data, and one study found erythropoietin cost-effective. CONCLUSIONS: We 
found that studies were difficult to compare, with inclusion criteria and compara-
tors varying among studies. Notably, most economic evaluations were substantially 
lacking depth and did not comply with common guidelines for pharmacoeconomic 
research. Although some articles found erythropoietin generally not cost-effec-
tive, their data did suggest otherwise within certain patient subgroups. Patients 
with lower preoperative hemoglobin levels, primary surgery and THA benefitted 
the most from erythropoietin. Additionally, most studies seemed to overestimate 
treatment costs, using outdated prices or neglecting competitively priced biosimi-
lars. Therefore, a more differentiated approach is required to elucidate the cost-
effectiveness of erythropoietin in orthopedic surgery, discriminating between total 
hip and knee arthroplasty.
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OBJECTIVES: The Colombian Health Care System has had a plan with limited ben-
efits, but since 2012, 57 drugs have been added to this plan. This research describes 
the trends of utilization and costs of medications covered by the Agreement 
029/2011 and compare them with those that were contained in the benefits 
plan. METHODS: A descriptive study involving a group of 3.8 million people affili-
ated with the Colombian Health Care System, in 110 cities from July 2011 until June 
2013. The variables were: new medications that were included, comparing them 
with homologous medications that were already in the plan, age, sex, dispensed 
quantities, and monthly billing. The study established the defined daily dosage per 
thousand inhabitants and day (DID), cost per thousand inhabitants and day (CID), 
cost per capita (CPC) and the rate of adoption or replacement medicines. RESULTS: 
The growth in consumption of new medications was 830.0%. The DID grew from 
4.3 to 42.9 with an increase of 905.5%. The medications with the highest growth 
were losartan/hydrochlorothiazide (15723%), esomeprazole (4193%), atorvastatin 
(1402%) and sertraline (298%). There was an increase in costs of US$16.40 in CID, 
which is equivalent to an increase of 61.7% and represents a rise of US$0.49 CPC 
per month. CONCLUSIONS: The consumption behavior of new medications and 
the economic implications for Colombia can be demonstrated. In particular, the 
growth of consumption of medications for chronic diseases can be seen, which 
would represent an increase to the entire population of the country of US$22.6 
million per month.
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OBJECTIVES: As new medications enter the market for rheumatoid arthritis (RA), 
economic evaluations of medications provide critical information for assessing cost 
effectiveness. The study objective was to estimate incremental cost per quality-
adjusted life year (QALY) of tofacitinib 5mg BID, a new treatment for moderate 
to severe RA after inadequate response to methotrexate, compared to available/
recommended treatment strategies as of 2014 using the Canadian 3rd-party-payer 
perspective and lifetime time horizon. METHODS: The cost utility model is an 
individual patient simulation through a Markov-like model. The model compares 
treatment strategies reflecting 2012 Canadian Rheumatology Association recom-
mendations for the pharmacological management of RA. Tofacitinib was included in 
the treatment algorithm similar to the anti-TNFs. Efficacy was measured using the 
continuous variable of Health Assessment Questionnaire Disability Index (HAQ-DI) 
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OBJECTIVES: Guidelines for primary care management of LBP in primary care rec-
ommend an initial period of watchful waiting before referral to PT. Some evidence 
suggests early PT may reduce future health care costs for LBP. This study compared 
LBP-related costs over a 1-year period in patients with acute LBP randomly assigned 
to usual care versus early PT. METHODS: Adults (age 18-60) visiting primary care 
with acute, non-specific LBP were recruited. All participants received advice and 
education about LBP and were randomized to 4 PT sessions or watchful waiting for 
4 weeks. Clinical outcomes and LBP-related costs were collected monthly for 1 year 
after enrollment using online diaries of health care utilization and work loss due to 
LBP. RESULTS: 196 participants were included of which 101 received early PT and 
95 usual care. Mean age was 37.5 years (+10.5) and 106 (54.1%) were female. Mean 
baseline Oswestry disability score was 40.4 (+13.0) and numeric pain rating was 5.0 
(+1.8). There were no differences between treatment groups for these characteristics 
or race/ethnicity, marital status, body mass index, smoking status, or medications 
prescribed at baseline. Repeated measures ANOVA found a significant group * time 
interaction for the outcome of pain (p< 0.028) across 1 year, but by the end of 1 year 
the early PT experienced a mean 0.31 points greater pain relief. Mean total LBP-
related costs over the year were $1,581 for early PT and $915 for usual care (mean 
difference $666, p= 0.067). The incremental cost-effectiveness ratio was $2,149 per 
1 point of pain intensity reduction per patient. CONCLUSIONS: Early PT showed 
small benefits in pain reduction across 1-year. The incremental cost effectiveness 
ratio may exceed willingness to pay thresholds.
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OBJECTIVES: Despite advances in hemostasis techniques, spinal fusion procedures 
result in significant blood loss and are associated with extensive post-surgery com-
plications. This study aimed to evaluate blood loss levels and its role in the economic 
burden of spinal fusion surgery. METHODS: A comprehensive literature review was 
conducted to evaluate the blood loss levels and economic burden of spinal fusion 
procedures for adolescent scoliosis (AS) and adult deformity (AD). In total, 75 articles 
were reviewed to collect blood loss and cost components such as operating (OR) 
time, blood loss, hospital length of stay (LoS), and transfusion needs. Costs of pre-
surgery care, surgical devices, and other surgical consumables were excluded from 
the analysis. RESULTS: Blood loss in spinal fusion surgery was found to be in the 0.6 
- 2.6L range depending on population and clinical setting. Patients required 0.6 to 1.0 
units of transfused blood, with varying levels of red blood cells, plasma, and platelets 
needed. The bulk of the economic burden of spinal fusion was due to utilization of 
hospital resources including OR time, LoS, and management of surgical side infec-
tion (SSI), with transfusion and anesthesia costs also contributing. OR time ranged 
from 2.7 hours in adults to 6.5 hours in adolescents. Post-operation LoS was in the 
3.8 - 8 day range and was strongly correlated with blood loss-related complications. 
Furthermore, with a mean cost of $23,860 per case and an incidence of 5.6%, SSI was 
noted as an uncommon but high-cost risk of spinal fusion. These components of 
economic burden add up to mean per-patient costs of $15,990 for AD patients and 
$12,647 for AS patients. CONCLUSIONS: Although surgeons currently use various 
tactics to manage blood loss during spinal fusion procedures, including electrocautery, 
blood transfusion, and topical hemostatic agents, blood loss and economic burden 
remain significant.
PMS43
evALuAting cLinicAL And econoMic outcoMeS ASSociAted with 
LiPoSoMAL BuPivAcAine (LB) for PoStSurgicAL PAin foLLowing totAL 
Knee ArthroPLASty (tKA)
Asche C.V.1, Kirkness C.S.1, Ren J.1, Kim M.1, Rainville E.2
1University of Illinois College of Medicine at Peoria, Peoria, IL, USA, 2OSF Saint Francis Medical 
Center, Peoria, IL, USA
OBJECTIVES: In response to increasing demand and limited resources, hospitals are 
exploring more efficient methods to perform TKA. The objective of this study was to 
examine the clinical and economic outcomes associated with using local infiltration 
of LB to manage postsurgical pain following TKA. METHODS: This study compared 
134 consecutive patients whose postsurgical pain following TKA was managed using 
local infiltration of LB (study group) to 134 historical patients who received continu-
ous nerve block with elastomeric pumps (control group). Groups were matched on 
clinical and demographic variables, including age, gender, race, and comorbidities, 
and sample size was based on estimated effect sizes. Outcomes examined included 
use of postsurgical opioid and non-opioid analgesics, time to ambulation, distance 
walked, pain scores, adverse effects, length of stay (LOS), discharge status, and total 
hospital costs. RESULTS: Significantly more patients in the study group (22%) were 
able to ambulate on the day of surgery than in the control group (3%) (p< 0.05). The 
study group had more patients discharged in 3 days or less (50%) than the control 
group (19%) (p< 0.05), and had a shorter mean LOS (2.8 ±1.7 days vs. 3.2±1.6 days). 
Total hospital costs were $366 less in the study group ($8,816/patient) than in the 
control group ($9,182/patient), which was mainly attributed to differences in the cost 
of room and board ($1,449 vs. $1,721, p< 0.05). After multivariate regression, adjusted 
cost savings in the study group were $457/patient (p< 0.05). No differences were found 
between in pain scores, opioid analgesic use, adverse events, or 30-day readmis-
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OBJECTIVES: Condoliase, an enzyme that specifically degrades glycosaminogly-
cans, main constituents of the nucleus pulposus, and reduces the compressions on 
nerves, can serve as a less-invasive curative treatment for patients with lumbar disc 
herniation and is expected to reduce associated medical cost due to shortened hos-
pital stays. This study aims to evaluate the cost-effectiveness of the treatment with 
condoliase compared with conventional surgical therapy in the Japanese healthcare 
system. METHODS: A Markov model was developed to estimate quality-adjusted 
life year (QALY) and associated costs over 1 year. QOL scores were converted from 
corresponding Oswestry Disability Index (ODI). ODI of condoliase group came from 
the results of a phase 3, multicenter, double-blind, randomized placebo-controlled 
study conducted in Japan. ODI of surgery group was estimated from the values 
obtained from published literatures. The risk of re-operation after treatment was 
considered during calculation. Surgical treatment costs and re-operation costs were 
collected and estimated using a Japanese administrative claims database (Japan 
Medical Data Center, JMDC). Payer perspective was adopted, and discounting was 
not applied due to the short timeframe of the analysis. One-way sensitivity analysis 
was performed to assess the impact of parameter uncertainty on the model’s con-
clusion. RESULTS: Average cost and effectiveness gained per patient for condoliase 
group and surgery group were 385,344 JPY vs. 798,919 JPY, 0.694 QALY vs. 0.685 QALY, 
respectively, meaning condoliase group was dominant compared to surgery group. 
One-way sensitivity analysis showed the robustness of this result. CONCLUSIONS: 
From the payer perspective, treatment with condoliase for patients with lumbar disc 
herniation in Japan is expected to reduce medical costs compared to conventional 
surgery treatment even taking into account the uncertainties.
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OBJECTIVES: Rheumatoid Arthritis (RA) destroys synovial joints and generates 
pain. Its prevalence in Chile has been estimated to be 0.46% (IC 95% 0.24-0.8). 
Available drugs for treatment include conventional synthetic Disease-Modifying 
Antirheumatic Drugs (csDMARDs), biological therapies and a new drug approved for 
treatment after failure of csDMARDs: tofacitinib. The aim of this study is to compare 
the costs-effectiveness of tofacitinib relative to biological therapies as an initial 
treatment in adults with RA after failure of methotrexate in Chile. METHODS: A 
simulation model of individual patients compared two treatment sequences for RA: 
tofacitinib vs biological therapy as initial medications; always assuming a combina-
tion therapy with methotrexate; biological therapies validated with rheumatologists 
and included in the model were etanercept, infliximab, tocilizumab, adalimumab, 
rituximab and salvage therapy (defined by experts). The characteristics of the 
patient included: age, weight, initial HAQ score, and clinical response to short and 
long term treatment. HAQ scores were used to calculate utilities, measured in QALYs 
based on literature information. All costs were obtained from public tenders and 
official reports from Chilean Ministry of Health. The analysis was made from third 
payer perspective with one, five, ten years and lifetime horizon. Annual discount 
rate was 3% for costs and outcomes. Results are expressed in USD2014 (US$1 = 
CLP$600) RESULTS: Total costs, for year one of treatment was US$9,627 starting the 
sequence with tofacitinib and US$11,638 starting with etanercept; obtained HAQ-
QALYs were 0.76 and 0.68, respectively. The total cost of the sequence strategy for 
lifetime horizon initiating with tofacitinib, was US$236,373 compared to the treat-
ment with biological therapy: US$259,403 with a difference of 0.62HAQ-QALY for 
utility. The costs included the drug, administration and health care. CONCLUSIONS: 
The sequence of treatment initiating with tofacitinib for RA Arthritis is a dominant 
strategy compared to biological therapies used in Chile. Net savings with this drug 
is US$35,006
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OBJECTIVES: Primary Total Hip Arthroplasty(THA) provides quality of life to 
patients and is cost-effective. Improvements to implant life have focused on the 
bearing surface with ceramic-on-polyethylene (CoP) bearing use growing rapidly 
due to evidence of longer implant life. We sought to determine if the increased 
CoP cost over the metal-on-polyethylene (MoP) provides enough benefit through 
lower revision rate to justify its utilization. METHODS: A Markov decision model 
was designed to determine the reduction in CoP 20-year revision rate required 
to make this implant cost-effective compared to MoP. Premier’s 2012 Research 
Database provided hospitalization costs for primary and revision surgeries. The 
Orthopedic Research Network (ORN) provided aggregated implant purchase price 
information. The HealthEast Joint Registry was the source of the MoP revision rate 
used for comparison. At each 10-year age increment/bearing cost condition, the 
CoP revision rate was varied until the lifetime costs were equal for the 2 different 
bearings. RESULTS: The sample included 20,398 patients aged 45-89+ from 475 US 
hospitals with identified bearing surfaces. CoP vs. MoP surface cost differences were 
$325+/-$177(p= 0.014) and $1,003+/-$710(p= 0.003), respectively, based on unadjusted 
and adjusted analysis of Premier data. ORN reports indicated a $600 difference 
in 2012. Revision costs were $23,628+/-$385 on 8,566 patients. HealthEast’s data 
indicates a 20-year MoP revision rate of 14.5/100THAs. An inflection in the revision 
scores (and changes) using results of a mixed treatment comparison (first 6 months) 
and data from long-term extension trials (later treatment periods). Where available, 
meta-analysis data were used to estimate adverse events incidence, followed by 
individual trial data and registry estimates. Canadian data from published sources 
were used to derive healthcare resource utilization costs and EuroQol-5D scores 
from HAQ-DI scores. All costs were estimated in 2014 Canadian dollars. Probabilistic 
and one-way sensitivity analyses were completed on analytical horizon, event rates, 
and efficacy thresholds. RESULTS: After running the model for 100,000 simula-
tions of moderate to severe RA patients, the treatment arm including tofacitinib 
had lifetime costs of $298,434 with 8.17 QALYs. Comparatively, the treatment arm 
excluding tofacitinib had a lifetime cost of $305,158 with 7.88 QALYs. Therefore, a 
treatment strategy including tofacitinib is dominant with lower costs and greater 
effectiveness. One-way and probabilistic sensitivity analysis reflected the robust-
ness of these results. CONCLUSIONS: The inclusion of tofacitinib into the treatment 
strategy for moderate to severe RA is a dominant strategy in Canada (lower cost 
and increased QALYs).
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic inflammatory condition with 
significant economic burden. Tofacitinib is an oral Janus kinase inhibitor indicated 
in the US for the treatment of moderate to severe RA in patients with inadequate 
response to methotrexate. Given the similarity of indications across available 
therapies, economic evaluation of alternate treatment strategies could inform 
US formulary decisions. We estimated incremental cost-effectiveness ratios of 
tofacitinib after methotrexate failure in a treatment sequence compared with 
a similar sequence without tofacitinib from a US third-party payer’s perspec-
tive. METHODS: The model estimated costs and outcomes of RA treatment 
with a pre-specified “treatment sequence” (sequential methotrexate, tofacitinib, 
adalimumab, abatacept, tocilizumab, rituximab) versus a “comparator sequence” 
(sequential methotrexate, etanercept, adalimumab, abatacept, tocilizumab, rituxi-
mab). Alternative sequences were considered. Efficacy was assessed by Health 
Assessment Questionnaire (HAQ) and compared using mixed treatment com-
parison and data from long-term extension trials. Adverse event data were from 
published meta-analyses and trials of tofacitinib and comparators. Patient char-
acteristics were based on tofacitinib clinical trials (NCT00856544; NCT00847613; 
NCT00853385). RA-related costs were from published data mapping HAQ onto 
healthcare resource utilization in US patients with RA. Indirect costs were not con-
sidered. RESULTS: From a US third-party payer’s perspective, the predicted lifetime 
cost of “treatment sequence” including tofacitinib was $509,047 versus $546,860 for 
“comparator sequence” without tofacitinib, with the difference primarily driven by 
drug cost. The “treatment sequence” with tofacitinib resulted in an additional 0.11 
quality-adjusted life years versus “comparator sequence.” Probabilistic sensitivity 
analysis suggested the probability that tofacitinib is cost-effective as second-line 
therapy is 64.0% at a threshold of $100,000. CONCLUSIONS: Our model suggests 
that including tofacitinib as second-line therapy following methotrexate failure 
is a cost-effective alternative versus a “comparator sequence” without tofacitinib. 
Sensitivity analysis reiterated robustness of the findings and cost-effectiveness 
of including tofacitinib. Results of alternate treatment sequence comparisons 
were similar.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic inflammatory disorder of the 
musculoskeletal system. After inadequate response (IR) to anti-tumor necrosis fac-
tor (anti-TNF) treatments, the clinical and economic value of alternative biologic 
agents is unclear. We sought to estimate the cost-effectiveness of tocilizumab 
versus abatacept from a U.S. payer perspective. METHODS: We constructed a 
treatment-regimen based cohort model with a lifetime horizon. The model evalu-
ated the treatment comparison of tocilizumab (162mg every other week with 
escalation to weekly for inadequate responders) vs. abatacept (125mg, weekly). In 
this comparison, treatment initiation was followed by a certolizumab-tofacitinib-
rituximab-palliative care sequence. Treatment response rates were applied every 
6 months. Health related quality of life was mapped to the health assessment 
questionnaire (HAQ) for RA. Mortality was modelled allowing for both non-RA and 
RA-specific mortality predicted by the HAQ. Costs were derived from published 
sources and included drug treatment, monitoring, and direct medical resource 
utilization. Costs and QALYs were discounted at 3%. Sensitivity analyses were 
performed to test the robustness of the model results. RESULTS: Comparing the 
two initial treatments, tocilizumab dominated abatacept yielding better outcomes 
and fewer costs. Probabilistic sensitivity analyses indicated substantial uncer-
tainty, yet the mean estimates remained consistent with the deterministic results. 
Tociluzumab had an 89% probability of being cost-effective at $50,000/QALY. The 
one-way sensitivity analysis indicated that the parameters related to baseline 
HAQ and improvement in the ACR 50 and 70 rates had the most impact on model 
results. CONCLUSIONS: Management of TNF-IR patients with RA represents a 
challenge for the health care system. Compared to abatacept, tocilizumab appears 
to represent a lower cost treatment option with improved outcomes. However, 
with the attendant uncertainty, head-to-head trials of these agents may be 
warranted.
